Max Chat
Share chart Biomea Fusion, Inc.
Extended chart
Simple chart
About Biomea Fusion, Inc.
Biomea Fusion, Inc., биофармацевтическая компания, занимается открытием, разработкой и коммерциализацией необратимых малых молекул для лечения пациентов с генетически определенными видами рака. Его ведущим продуктом-кандидатом является BMF-219, перорально биодоступный, мощный и селективный необратимый ингибитор MENIN, регулятора транскрипции в онкогенной передаче сигналов при множественных раковых заболеваниях. Компания была основана в 2017 году и имеет штаб-квартиру в Редвуд-Сити, штат Калифорния.
Main settings
IPO date
2021-04-16
ISIN
US09077A1060
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Underestimation
| Title | Value | Grade |
| P/S | 0 | 0 |
| P/BV | 2.72 | 6 |
| P/E | 0 | 0 |
Efficiency
| Title | Value | Grade |
| ROA | -98.92 | 0 |
| ROE | -125.38 | 0 |
| ROIC | -61.27 | 0 |
Dividends
| Title | Value | Grade |
| Dividend yield | 0 | 0 |
| DSI | 0 | 0 |
| Average dividend growth | 0 | 0 |
Debt
| Title | Value | Grade |
| Debt/EBITDA | -0.0609 | 10 |
| Debt/Ratio | 0.1097 | 10 |
| Debt/Equity | 0.55 | 9 |
Growth impulse
| Title | Value | Grade |
| Yield Revenue, % | 0 | 0 |
| Yield Ebitda, % | 2618.3 | 10 |
| Yield EPS, % | 666.78 | 10 |
Prices
| Price | Min. | Max. | Change | Changes in the industry | Changes in the index | |
| Yesterday | 2.61 $ | 0 $ | 0 $ | -9.58 % | 0 % | 0 % |
| Week | 2.63 $ | 0 $ | 0 $ | -10.27 % | 0 % | 0 % |
| Month | 1.48 $ | 2.36 $ | 2.61 $ | +59.46 % | 0 % | 0 % |
| Three month | 1.73 $ | 1.39 $ | 2.86 $ | +36.42 % | 0 % | 0 % |
| Half a year | 4.16 $ | 1.39 $ | 4.48 $ | -43.27 % | 0 % | 0 % |
| Year | 7.54 $ | 1.39 $ | 12.41 $ | -68.7 % | 0 % | 0 % |
| 3 years | 12.26 $ | 1.39 $ | 41.8 $ | -80.75 % | 0 % | 0 % |
| 5 years | 1.39 $ | 1.39 $ | 41.8 $ | +187.77 % | 0 % | 0 % |
| 10 years | 1.39 $ | 1.39 $ | 41.8 $ | +187.77 % | 0 % | 0 % |
| Year to date | 4.27 $ | 1.39 $ | 4.48 $ | -44.73 % | 0 % | 0 % |
Main owners
| Institutions | Volume | Share, % |
| Aisling Capital Management LP | 799 | 2.22 |
| FMR, LLC | 5 | 14.9 |
| State Street Corporation | 4 | 12.48 |
| Cormorant Asset Management, LP | 4 | 9.93 |
| Laurion Capital Management, LP | 3 | 7.57 |
| Baker Brothers Advisors, LLC | 2 | 5.87 |
| Blackrock Inc. | 2 | 5.49 |
| Vanguard Group Inc | 1 | 3.8 |
| Janus Henderson Group PLC | 1 | 3.58 |
| Driehaus Capital Management, LLC | 1 | 3.32 |
Contained in ETF
| ETF | Share, % | Profitability for 1 year, % | Commission, % |
| Principal Healthcare Innovators ETF | 0.03021 | -3.92 | 0.35 |
| Future Tech ETF | 0.03021 | 479.5 | 0.35 |
Similar companies
P/E & P/BV
Company management
| Head | Job title | Payment | Year of birth |
| Mr. Thomas Andrew Butler | Co-Founder, Chairman & CEO | 921.14k | 1981 (44 years) |
| Mr. Ramses M. Erdtmann | Co-Founder, President, COO & Director | 659.53k | 1963 (62 years) |
| Mr. Franco Valle | CFO & Principal Accounting Officer | 651.77k | 1981 (44 years) |
| Mr. Heow Tan | Chief Technology & Quality Officer | N/A | 1959 (66 years) |
| Ms. Naomi Cretcher | Chief People Officer | N/A | |
| Dr. Thorsten Kirschberg Ph.D. | Executive Vice President of Chemistry | N/A | 1970 (55 years) |
| Dr. Stephan Morris M.D. | Chief Development Officer | N/A | |
| Mr. Ravi Upasani | Executive Vice President of Intellectual Property | N/A | |
| Dr. Juan Pablo Frias M.D. | Chief Medical Officer | N/A | |
| Caroline Perez- Dupont | Senior Vice President of Contracts |
About company
Address: United States, Redwood City. CA, 900 Middlefield Road - Open in google maps, Open in yandex maps
Website: https://biomeafusion.com
Website: https://biomeafusion.com
